Affymetrix and Baylor College of Medicine Enter into Licensing Agreement
December 05 2006 - 8:00AM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) and Baylor College of Medicine
announced today that Baylor has obtained a non-exclusive, worldwide
license to a number of Affymetrix patents covering comparative
genomic hybridization (CGH) microarray services in Clinical
Laboratory Improvement Amendments (CLIA) environments. Financial
details of the license were not disclosed. �Since the inception of
our licensing program, Affymetrix has�signed many agreements that
validate our position as�the�clear market�innovator and�leader,�
said Alan Sherr, vice president and chief counsel for Licensing at
Affymetrix. �This agreement with Baylor College of Medicine is
another example of a mutually beneficial relationship that enables
both companies to better serve customers within the growing
microarray market.� �Comparative genomic hybridization microarrays
represent one of the biggest advancements of the last 30 years in
clinical genetic laboratory testing. The technology is being used
to identify specific genetic abnormalities in many children that
have developmental disabilities with previously unknown causes,�
said Arthur Beaudet,�M.D., professor and chairman of the Department
of Molecular and Human Genetics at Baylor College of Medicine.
About Baylor College of Medicine Baylor College of Medicine in
Houston, the only private medical school in the Greater Southwest,
was founded in 1900 and is today an internationally respected
medical and research institution known for excellence in education,
research and patient care. For more information about Baylor
College of Medicine, please visit the company's website at
http://www.bcm.edu. About Affymetrix Affymetrix scientists invented
the world's first high-density microarray in 1989 and began selling
the first commercial microarray in 1994. Since then, Affymetrix
GeneChip� technology has become the industry standard in molecular
biology research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties relating to commercial success of the licensing
agreement with Baylor College of Medicine discussed in this press
release; risks of the Company's ability to achieve and sustain
higher levels of revenue, higher gross margins, reduced operating
expenses; uncertainties relating to technological approaches,
manufacturing, product development; personnel retention;
uncertainties related to cost and pricing of Affymetrix products;
dependence on collaborative partners; uncertainties relating to
sole source suppliers; uncertainties relating to FDA and other
regulatory approvals; competition; risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K/A for the year ended December 31, 2005, and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo,
and GeneChip are registered trademarks owned or used by Affymetrix
Inc. Affymetrix Inc. (Nasdaq:AFFX) and Baylor College of Medicine
announced today that Baylor has obtained a non-exclusive, worldwide
license to a number of Affymetrix patents covering comparative
genomic hybridization (CGH) microarray services in Clinical
Laboratory Improvement Amendments (CLIA) environments. Financial
details of the license were not disclosed. "Since the inception of
our licensing program, Affymetrix has signed many agreements that
validate our position as the clear market innovator and leader,"
said Alan Sherr, vice president and chief counsel for Licensing at
Affymetrix. "This agreement with Baylor College of Medicine is
another example of a mutually beneficial relationship that enables
both companies to better serve customers within the growing
microarray market." "Comparative genomic hybridization microarrays
represent one of the biggest advancements of the last 30 years in
clinical genetic laboratory testing. The technology is being used
to identify specific genetic abnormalities in many children that
have developmental disabilities with previously unknown causes,"
said Arthur Beaudet, M.D., professor and chairman of the Department
of Molecular and Human Genetics at Baylor College of Medicine.
About Baylor College of Medicine Baylor College of Medicine in
Houston, the only private medical school in the Greater Southwest,
was founded in 1900 and is today an internationally respected
medical and research institution known for excellence in education,
research and patient care. For more information about Baylor
College of Medicine, please visit the company's website at
http://www.bcm.edu. About Affymetrix Affymetrix scientists invented
the world's first high-density microarray in 1989 and began selling
the first commercial microarray in 1994. Since then, Affymetrix
GeneChip(R) technology has become the industry standard in
molecular biology research. Affymetrix technology is used by the
world's top pharmaceutical, diagnostic and biotechnology companies
as well as leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties relating to commercial success of the licensing
agreement with Baylor College of Medicine discussed in this press
release; risks of the Company's ability to achieve and sustain
higher levels of revenue, higher gross margins, reduced operating
expenses; uncertainties relating to technological approaches,
manufacturing, product development; personnel retention;
uncertainties related to cost and pricing of Affymetrix products;
dependence on collaborative partners; uncertainties relating to
sole source suppliers; uncertainties relating to FDA and other
regulatory approvals; competition; risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K/A for the year ended December 31, 2005, and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo,
and GeneChip are registered trademarks owned or used by Affymetrix
Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024